Table 1.
Characteristics of 2496 transplant recipients included in the analysis according their exposure to hydrochlorothiazide during follow-up
| Characteristics | Whole Sample, n=2496 | No Hydrochlorothiazide, n=2217 | Hydrochlorothiazide, n=279 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Not Available (Missing) | Mean | SD | Not Available (Missing) | Mean | SD | Not Available (Missing) | Mean | SD | |
| Recipient age, yr | 0 | 49 | 14 | 0 | 49 | 14 | 0 | 50 | 13 |
| Not Available (Missing) | n | % | Not Available (Missing) | n | % | Not Available (Missing) | n | % | |
|---|---|---|---|---|---|---|---|---|---|
| Men | 0 | 1538 | 62 | 0 | 1353 | 61 | 0 | 185 | 66 |
| Initial nephropathy | 0 | 0 | 0 | ||||||
| Chronic tubulointerstitial nephritis/ADPKD/congenital uropathy | 962 | 39 | 880 | 40 | 82 | 29 | |||
| Diabetes | 467 | 19 | 413 | 19 | 54 | 19 | |||
| Glomerulopathy | 643 | 26 | 567 | 26 | 76 | 27 | |||
| Other | 232 | 9 | 206 | 9 | 26 | 9 | |||
| Vascular nephropathy | 192 | 8 | 151 | 7 | 41 | 15 | |||
| KRT | 46 | 41 | 5 | ||||||
| Hemodialysis | 1757 | 72 | 1544 | 71 | 213 | 78 | |||
| Peritoneal dialysis | 217 | 9 | 200 | 9 | 17 | 6 | |||
| Preemptive transplantation | 476 | 19 | 432 | 20 | 44 | 16 | |||
| Type of transplantation | 0 | 0 | 0 | ||||||
| Combined kidney-pancreas | 282 | 11 | 254 | 11 | 28 | 10 | |||
| Kidney | 2155 | 86 | 1909 | 86 | 246 | 88 | |||
| Pancreas | 59 | 2 | 54 | 2 | 5 | 2 | |||
| Retransplantation | 0 | 436 | 17 | 0 | 399 | 18 | 0 | 37 | 13 |
| Deceased donor | 0 | 2200 | 88 | 0 | 1948 | 88 | 0 | 252 | 90 |
| HLA-A -B -Dr mismatches ≥4 | 2 | 1264 | 51 | 2 | 1113 | 50 | 0 | 151 | 54 |
| Cold ischemia time ≥18 h | 21 | 1018 | 41 | 20 | 882 | 40 | 1 | 136 | 49 |
| Delayed graft function | 78 | 811 | 34 | 73 | 705 | 33 | 5 | 106 | 39 |
| Rejection | 0 | 301 | 12 | 0 | 264 | 12 | 0 | 37 | 13 |
| Other malignancies | 0 | 193 | 8 | 0 | 163 | 7 | 0 | 30 | 11 |
| Induction treatment | 0 | 0 | 0 | ||||||
| Depleting | 1219 | 49 | 1098 | 50 | 121 | 43 | |||
| Nondepleting | 1213 | 49 | 1066 | 48 | 147 | 53 | |||
| None | 64 | 3 | 53 | 2 | 11 | 4 | |||
| Calcineurin inhibitors | 0 | 0 | 0 | ||||||
| Cyclosporin | 361 | 14 | 303 | 14 | 58 | 21 | |||
| Tacrolimus | 2108 | 84 | 1892 | 85 | 216 | 77 | |||
| None | 27 | 1 | 22 | 1 | 5 | 2 | |||
| Steroid-free regimen | 0 | 482 | 19 | 0 | 416 | 19 | 0 | 66 | 24 |
| mTOR inhibitors during follow-up | 0 | 434 | 17 | 0 | 364 | 16 | 0 | 70 | 25 |
No hydrochlorothiazide (HCTZ) corresponds to patients never exposed to HCTZ during their follow-up. The HCTZ group corresponds to the other patients. ADPKD, autosomal dominant polycystic kidney disease; HLA, human leucocyte antigen; mTOR, mammalian target of rapamycin.